Investment trust insider on Jupiter European Opportunities James Carthew: why I’m taking profits in Europe’s star trust Whenever I sit down to look at the European trusts, I find it way too easy to get bogged down in the macro story. There are plenty of reasons to worry about Europe – Brexit, Italy, Greece, the […]
Investment trust insider on emerging market bonds – James Carthew: it’s high time for emerging market bonds The third quarter of the year looks set to be a bumper period for launches of new investment trusts but, as often happens, markets are not playing ball. Emerging markets have switched into reverse gear again with the twin […]
Investment trust insider on Henderson Alternative Strategies James Carthew: ‘bargain’ trust poses too many questions For a discount player, there are very few pockets of real value in the investment companies market today. Boards are much better at controlling discounts and the search for income means that very few funds with a yield are on […]
Investment Trust Insider on Augmentum Fintech James Carthew: Augmentum’s mature focus stands out I regularly moan that the UK market is not very good at financing early stage British businesses. However, in March this year, we saw the launch of a new fund dedicated to supporting the burgeoning fintech industry in the UK, Augmentum Fintech (AUGM). The fund is […]
Investment Trust Insider on Cuba James Carthew: classic closed-end chance in Cuban property One of the great things about the investment companies sector is that it is always evolving. The closed-end structure is the ideal vehicle for an incredibly diverse range of assets as is demonstrated by the upcoming London listing of a Cuba property […]
After months of volatility, investment trusts in the biotech and commodity sectors were the winners in July in both price and NAV terms, according to latest figures. In its monthly investment companies round-up, trust analysts QuotedData revealed biotech and commodity investment trusts – which have had a difficult time over the last few months in […]
Investment Trust Insider on Syncona James Carthew: the problem with Syncona’s big premium Regular readers of this column will have realised that I often have as much of a problem with investment trusts trading on very high premiums as I do with trusts trading on very wide discounts. I explained a couple of weeks ago […]
Investment Trust Insider on Riverstone Energy James Carthew: Riverstone’s history restricts oil boom effect BP’s announcement on Friday that it is spending $10.5 billion to buy BHP’s US shale oil investments, comprising considerable acreage in the Permian and Eagle Ford basins plus gas-producing fields in the southern states of the US, is a good cue […]
Investment Trust Insider on how to grow trusts James Carthew: imponderable questions in quest for scale Last week I addressed the uphill battle Ashoka India Equity (AIE) faces if it wants to expand, having raised just £46.5 million in its flotation. It is by no means the smallest fund out there, however. Many of the […]
Investment Trust Insider on recent new issues – James Carthew: can Ashoka overcome a disappointing launch? It has been a week of contrasts in the new issue market. Tritax EuroBox (EBOX) raised its maximum target of £300 million in an issue that was ‘significantly oversubscribed’ and Hipgnosis Songs Fund (SONG) raised over £200 million. Whereas […]
